Effects of 1,25‐dihydroxyvitamin D3 on the distribution of androgen and vitamin D receptors in human prostate neonatal epithelial cells
- 27 November 2002
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 88 (3) , 609-622
- https://doi.org/10.1002/jcb.10371
Abstract
Although many studies have examined the mechanisms of 1,25‐dihydroxyvitamin D3 (calcitriol or 1,25 D) action in different prostate cancer cell lines, little is known regarding the influence of this steroid on the normal prostate. The presence of both VDR and AR in normal prostatic tissues raises the distinct possibility of an important role for this hormone in the normal gland. In order to ascertain the possible role of 1,25 D on both AR and VDR in the normal prostate, the effects of calcitriol and dihydrotestosterone (DHT) on the normal human neonatal prostatic epithelial cell line, 267B‐1, were examined. These studies were approached by focusing on how 1,25 D in the presence or absence of DHT affects the distribution of AR and VDR in the cytoplasmic and nuclear compartments of the cells in terms of their protein levels and DNA binding activities. Immunoblot analyses show that 1,25 D increases the AR protein level in both the cytoplasmic and nuclear fractions but not the VDR protein level. On the other hand, the gel shift assays demonstrate that 1,25 D increases both the AR– and VDR–DNA binding activities in the nuclear fraction, whereas there is no increase in DNA binding activities in the cytoplasmic fraction. Addition of DHT along with 1,25 D does not affect the DNA binding activities of both AR and VDR. Overall, these studies suggest that 1,25 D actions on the normal prostate cells may be mediated independently through AR and VDR, respectively.Keywords
This publication has 32 references indexed in Scilit:
- IN VITRO AND IN VIVO EFFECTS OF VITAMIN D (CALCITRIOL) ADMINISTRATION ON THE NORMAL NEONATAL AND PREPUBERTAL PROSTATEJournal of Urology, 2000
- Characterization of vitamin D receptor immunoreactivity in human bone cellsBone, 2000
- 1 ,25-Dihydroxyvitamin D3 Inhibits Prostate Cancer Cell Growth by Androgen-Dependent and Androgen-Independent MechanismsEndocrinology, 2000
- The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties RevealedJournal of Bone and Mineral Research, 1998
- Induction of Apoptosis and Altered Nuclear/Cytoplasmic Distribution of the Androgen Receptor and Prostate-Specific Antigen by 1α,25-Dihydroxyvitamin D3in Androgen-Responsive LNCaP CellsBiochemical and Biophysical Research Communications, 1997
- Control of 1,25-dihydroxyvitamin D3 receptor-mediated enhancement of osteocalcin gene transcription: effects of perturbing phosphorylation pathways by okadaic acid and staurosporineEndocrinology, 1995
- 1,25-Dihydroxyvitamin D3 modulates phosphorylation of serine 205 in the human vitamin D receptor: site-directed mutagenesis of this residue promotes alternative phosphorylationBiochemistry, 1994
- The influence of steroidal and nonsteroidal estrogens on the 5α-reduction of testosterone by the ventral prostate of the ratThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells.The Journal of cell biology, 1984
- 1,25-DIHYDROXYVITAMIN D3AND MALIGNANT MELANOMA: THE PRESENCE OF RECEPTORS AND INHIBITION OF CELL GROWTH IN CULTUREEndocrinology, 1981